Optimal design of a population pharmacodynamic experiment for ivabradine

被引:34
作者
Duffull, SB
Mentré, F
Aarons, L
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England
[2] CHU Pitie Salpetriere, INSERM, U436, F-75013 Paris, France
关键词
pharmacodynamics; ivabradine; optimal design; population analysis; Fisher information matrix;
D O I
10.1023/A:1011035028755
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To design a parsimonious population pharmacodynamic experiment that has the same or greater efficiency than that provided by two phase I studies. Methods. The design was based on optimization of the population Fisher information matrix. Options for optimization were (1) determination of the optimal sampling times for each group ("group" represents a group of subjects that have identical design characteristics), (2) determination of the optimal doses for each group, and (3) determination of the optimal group structure. Results. (1) Optimizing the sampling times, while retaining only four unique times per group, provided a more parsimonious experiment with the same efficiency as the original "study" that involved on average 10 samples per subject. Splitting sampling times between the first dose and a steady-state dose gave the most informative design. (2) The optimal dose was the same in all groups and was the upper bound of the dose range. (3) The optimal population design consisted of only one group with four unique sampling times that are the same for all subjects. Conclusion. A population pharmacodynamic trial design is presented that is more parsimonious than the original study and would be appropriate for inclusion in a premarketing clinical study.
引用
收藏
页码:83 / 89
页数:7
相关论文
共 18 条
[1]   Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients [J].
Cosson, VF ;
Fuseau, E .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1999, 27 (02) :149-171
[2]   INCORPORATING PRIOR PARAMETER UNCERTAINTY IN THE DESIGN OF SAMPLING SCHEDULES FOR PHARMACOKINETIC PARAMETER-ESTIMATION EXPERIMENTS [J].
DARGENIO, DZ .
MATHEMATICAL BIOSCIENCES, 1990, 99 (01) :105-118
[3]   OPTIMAL SAMPLING TIMES FOR PHARMACOKINETIC EXPERIMENTS [J].
DARGENIO, DZ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1981, 9 (06) :739-756
[4]   A pharmacokinetic simulation model for ivabradine in healthy volunteers [J].
Duffull, SB ;
Chabaud, S ;
Nony, P ;
Laveille, C ;
Girard, P ;
Aarons, L .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 10 (04) :285-294
[5]   Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers [J].
Duffull, SB ;
Aarons, L .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 10 (04) :275-284
[6]  
ENDRENYI L, 1981, KINETIC DATA ANAL DE, P137
[7]   INTERPRETATION OF SIMULATION STUDIES FOR EFFICIENT ESTIMATION OF POPULATION PHARMACOKINETIC PARAMETERS [J].
ETTE, EI ;
KELMAN, AW ;
HOWIE, CA ;
WHITING, B .
ANNALS OF PHARMACOTHERAPY, 1993, 27 (09) :1034-1039
[8]  
Fedorov VV., 1972, THEORY OPTIMAL EXPT
[9]   DESIGNS FOR POPULATION PHARMACODYNAMICS - VALUE OF PHARMACOKINETIC DATA AND POPULATION ANALYSIS [J].
HASHIMOTO, Y ;
SHEINER, LB .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (03) :333-353
[10]   Design of cross-over trials for pharmacokinetic studies [J].
Jones, B ;
Wang, J ;
Jarvis, P ;
Byrom, W .
JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 1999, 78 (1-2) :307-316